Human Growth Hormone Market Size is expected to reach US$ 19.8 Billion by 2034, from US$ 5.9 Billion in 2024, growing at a CAGR of 12.7%.

Human Growth Hormone Market is segmented By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Prader-Willi Syndrome, and Others) and Route of Administration (Oral, Intravenous, Subcutaneous, and Intramuscular)

This statistic displays the total global human growth hormone market in 2022 and a forecast for 2032, measured in billion U.S. dollars. In 2022, the total market was estmated at 3.4 billion U.S. dollars. Leading application areas of growth hormones are growth hormone deficiency, Idiopathic Short Stature (ISS), Turner syndrome, Prader-Willi syndrome, and Small for Gestational Age (SGA).

This statistic displays the total U.S. human growth hormone market from 2014 to 2025, measured in billion U.S. dollars. In 2016, the total market was estimated to stand at approximately 1.7 billion U.S. dollars. Among the leading application areas of growth hormones are growth hormone deficiency, Idiopathic Short Stature (ISS), Turner syndrome, Prader-Willi syndrome, and Small for Gestational Age (SGA).

The Human Growth Hormone Market Report Segments the Industry Into by Application (Growth Hormone Deficiency, Turner Syndrome, and More), Route of Administration (Subcutaneous, Intravenous, and More), Formulation (Short-Acting and Long-Acting), by Distribution Channel (Hospitals Pharmacies, and More), Patient Type (Adult and Pediatric), and Geography. The Market Sizes and Forecasts are Provided in Terms of Value (USD).

The market is expected to be valued at USD 3,946.6 million in 2025 and will be nearing USD 5,567.1 million by 2035, exhibiting a CAGR of 3.5% over the forecast period.

Metric	Value
Industry Size (2025E)	USD 3,946.6 Million
Industry Value (2035F)	USD 5,567.1 Million
CAGR (2025 to 2035)	3.5%

Country-wise Outlook

Country	CAGR (2025 to 2035)
United States	3.7%

Country	CAGR (2025 to 2035)
United Kingdom	3.3%

Region	CAGR (2025 to 2035)
European Union	3.4%

Country	CAGR (2025 to 2035)
Japan	3.2%

Country	CAGR (2025 to 2035)
South Korea	3.6%

Competitive Outlook

Company Name	Estimated Market Share (%)
Novo Nordisk A/S	12-16%
Pfizer Inc.	10-14%
Eli Lilly and Company	8-12%
Merck KGaA	6-10%
Ferring Pharmaceuticals	4-8%
Other Companies (combined)	45-55%

The global human growth hormone market size was valued at USD 6.11 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 11.47 Billion by 2033, exhibiting a CAGR of 6.88% during 2025-2033. North America currently dominates the market, holding a significant market share of 42.8% in 2024. The market is growing robustly due to the developed healthcare infrastructure and high incidence of HGH-related disorders like growth hormone deficiencies, Turner syndrome, and Prader-Willi syndrome. Government support in the form of favorable reimbursement policies, availability of leading pharmaceutical firms, including Pfizer and Eli Lilly, and advancements in recombinant DNA methods have also fueled the human growth hormone market share.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	USD 6.11 Billion
Market Forecast in 2033	USD 11.47 Billion
Market Growth Rate 2025-2033	6.88%

IMARC Group provides an analysis of the key trends in each sub-segment of the global human growth hormone market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on application, distribution channel and route of administration.

The Human Growth Hormone Market size is expected to reach a valuation of USD 22.0 billion in 2033 growing at a CAGR of 12.20%. The Human Growth Hormone Market research report classifies market by share, trend, demand, forecast and based on segmentation.

Growth Hormone Market size was valued at USD 4.75 Billion in 2024 and is projected to reach USD 7.66 Billion by 2031, growing at a CAGR of 6.80% during the forecasted period 2024 to 2031.

Growth Hormone Market: Definition/ Overview

Human growth hormone (HGH), also known as somatotropin, is a vital peptide hormone responsible for stimulating growth, cell division, and regeneration, playing a key role in human development. Produced by the pituitary gland, hGH is crucial for normal growth during childhood and adolescence. A deficiency in growth hormone (GH) occurs when the pituitary gland fails to produce adequate amounts, leading to growth hormone deficiency (GHD). This condition can result from various factors, including genetic disorders like Prader-Willi syndrome, Turner syndrome, and idiopathic short stature (ISS), all of which can cause delayed puberty and shorter stature.

While hGH is used therapeutically to treat growth hormone deficiencies and certain medical conditions, it is also often misused by older adults, athletes, and bodybuilders as an anabolic agent for performance enhancement and anti-aging purposes. However, the U.S. Food and Drug Administration (USFDA) has not approved growth hormone for these uses, as it is considered a restricted substance.

This statistic displays the distribution of the U.S. human growth hormone market from 2014 to 2025, sorted by application. In 2016, 6.3 percent of the market was generated by treatments of the Prader-Willi syndrome.

Learn more about Market Research Intellect's report_name, valued at current_value in 2024, and set to grow to forecast_value by 2033 with a CAGR of cagr_value (2026-2033).

Human Growth Hormone Market Outlook

The global human growth hormone market size was valued at approximately $6.1 billion in 2023 and is projected to reach around $10.8 billion by 2032, growing at a CAGR of 6.7% during the forecast period. This robust market growth is primarily driven by an increasing prevalence of growth hormone deficiencies, advancements in recombinant DNA technology, and rising awareness about the benefits of growth hormone therapy.

One of the crucial growth factors of the human growth hormone market is the rising incidence of growth hormone deficiency (GHD) and related disorders. GHD is a significant medical condition that affects both children and adults, leading to various physical and psychological issues. The availability of effective treatments, such as human growth hormone therapy, has contributed to improving the quality of life for affected individuals, thereby driving market demand. Moreover, advancements in diagnostic techniques have enabled early and accurate detection of GHD, further boosting the market's growth.

Another significant factor contributing to market growth is the increasing application of human growth hormone in treating conditions beyond GHD. These include Turner syndrome, idiopathic short stature, and children born small for gestational age. As medical research continues to uncover new therapeutic uses, the demand for growth hormone therapies is expected to rise. Furthermore, the growing aging population, which is more susceptible to growth hormone deficiencies, is likely to propel market expansion over the forecast period.

The advent of recombinant DNA technology has had a transformative impact on the human growth hormone market. This technology allows for the mass production of synthetic human growth hormone, ensuring a consistent supply of high-quality hormone therapy products. Additionally, the development of long-acting growth hormone formulations has improved patient compliance, as fewer doses are required. These technological advancements are expected to play a significant role in sustaining market growth.

Regionally, North America currently leads the market due to well-established healthcare infrastructure, high awareness levels, and significant investments in research and development. Europe follows closely, driven by similar factors. However, the Asia Pacific region is expected to witness the highest growth rate, attributed to increasing healthcare expenditures, rising awareness about growth hormone therapies, and improving healthcare infrastructure. The growing prevalence of growth hormone deficiencies in developing countries within this region also contributes to the market's potential for expansion.

The use of Growth Hormone Needle technology has become increasingly significant in administering human growth hormone therapies. These needles are designed to deliver precise doses of growth hormone, ensuring optimal therapeutic outcomes while minimizing discomfort for patients. The development of ultra-fine needles has enhanced patient compliance, particularly among children and individuals requiring frequent injections. As the market continues to expand, innovations in needle technology are expected to play a crucial role in improving the administration of growth hormone therapies. This advancement not only enhances the efficacy of treatments but also contributes to the overall patient experience, making hormone therapy more accessible and less daunting for users.

Product Type Analysis

The human growth hormone market is segmented based on product type into powder and solvent formulations. The powder form of human growth hormone holds a significant market share, largely due to its stability, ease of storage, and longer shelf-life. Powder formulations are particularly advantageous in regions with less developed cold chain infrastructure, as they can be stored at room temperature before reconstitution. Moreover, advancements in lyophilization techniques have improved the quality and efficacy of powder-based growth hormone products.

Solvent formulations of human growth hormone are also witnessing considerable demand, owing to their ready-to-use nature. These formulations are often preferred in clinical settings where immediate administration is required. The convenience of solvent-based growth hormone products is particularly beneficial for patients requiring frequent doses, such as those undergoing intensive hormone replacement therapy. Furt

Recent developments include: January 2022: Ascendis Pharma A/S (Denmark) received the European Commission's approval for TransCon hGH for paediatric growth hormone deficiency. TransCon hGH contains somatropin, which is used for paediatric patients diagnosed with growth hormone deficiency., January 2018: Ferring B.V. (Switzerland‎) recieved approval from US Food Drug and Administration for ZOMACTON injection recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency., March 2022: Ipsen Pharma (France) announced the investment in a new state-of-the-art electronic autoinjector for Somatuline Autogel/Somatuline Depot (lanreotide). This product is specifically designed to improve administration and the injection experience for patients.. Key drivers for this market are: Rising cases of growth hormone deficiency 29, Increasing awareness about the endocrine disorders, and effectiveness of growth hormones 29; Widener scope of application of growth hormones 30. Potential restraints include: Side-effects associated with the growth hormone therapy 30, High cost of treatment and lack of health insurance coverage 30. Notable trends are: Rising incidence of growth hormone deficiency boosts market growth.

Human Growth Hormone Market size was valued at USD 5.40 Billion in 2021 and is poised to grow from USD 5.84 Billion in 2022 to USD 10.98 Billion by 2030, at a CAGR of 8.2% during the forecast period (2023-2030).

According to Cognitive Market Research, the global recombinant human growth hormone market size will be USD 6125.6 million in 2024. It will expand at a compound annual growth rate (CAGR) of 4.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 2450.24 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1837.68 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1408.89 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 306.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 122.51 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.
The hospital pharmacy held the highest recombinant human growth hormone market revenue share in 2024.

Market Dynamics of Recombinant Human Growth Hormone Market

Key Drivers for Recombinant Human Growth Hormone Market

Rising Incidence of Growth Hormone Deficiency to Increase the Demand Globally

The rising incidence of hormone deficiency, including growth hormone deficiencies, is driving the recombinant human growth hormone market. As conditions like growth hormone deficiency become more prevalent, there is an increased demand for recombinant human growth hormone treatments to address these deficiencies effectively. Recombinant human growth hormone helps in stimulating growth and regulating metabolism, making it crucial for managing such deficiencies. The market growth is further supported by advancements in biotechnology, improved healthcare access, and increasing awareness among patients and healthcare providers about effective treatment options.

Advancements in Technology to Propel Market Growth

Advancements in technology have significantly impacted the recombinant human growth hormone market by improving the production processes and efficacy of recombinant human growth hormone products. Innovations in genetic engineering and biotechnological methods have enhanced the quality, purity, and scalability of recombinant human growth hormone. Techniques such as advanced protein expression systems and purification technologies have lowered production costs and increased availability. Additionally, technology-driven improvements in delivery systems and formulation options have expanded the therapeutic uses of recombinant human growth hormone, driving market growth and making it more accessible for treating growth disorders and other medical conditions.

Restraint Factor for the Recombinant Human Growth Hormone Market

High Cost of Recombinant Human Growth Hormone to Limit the Sales

The high cost of recombinant human growth hormone is a significant restraint in the market. Its production involves complex biotechnological processes, stringent quality control, and advanced manufacturing techniques, which contribute to its high price. Additionally, the cost of raw materials, regulatory compliance, and the need for specialized storage and distribution further elevate expenses. These factors make recombinant human growth hormone products expensive for consumers and healthcare systems, limiting accessibility and adoption and hindering market growth despite the increasing demand for growth hormone therapies.

Impact of Covid-19 on the Recombinant Human Growth Hormone Market

The COVID-19 pandemic significantly impacted the recombinant human growth hormone market by disrupting supply chains, halting clinical trials, and shifting healthcare priorities. However, it also accelerated interest in recombinant human growth hormone for treating COVID-19-related growth issues and recovery support. Increased focus on healthcare and biotechnology investments post-pandemic has led to a surge in recombinant human growth hormone research and development. Additionally, rising awareness about hormone deficiencies and advancements in recombinant technology are expected to drive future market growth, balancing the initial setbacks caused by the pandemic...

The Human Growth Hormone Market size was valued at USD 7.41 billion in 2023 and is projected to reach USD 16.69 billion by 2032, exhibiting a CAGR of 12.3 % during the forecasts period. The Human Growth Hormone (HGH) industry involves the manufacturing and selling of artificial HGH, also known as somatotropin, which is a peptide hormone that intrinsically promotes the growth of tissues, bones, and cells, cell division, and regeneration of tissue. The foremost uses of HGH are in the treatment of developmental disorders in children and the treatment of growth hormone deficiency patients of all age groups.HGH is used in the management of Turner syndrome, Prader-Willi syndrome, and chronic kidney disease. Currently, there has been a surge in trends that involve the utilization of HGH in the treatment of anti-aging therapy and performance boosting and its use also continues to spark controversy in terms of its ethical and legal issues. Technological developments, higher incidences of growth hormone deficiency, and an enhanced awareness of health are considered to be the key factors, which will help spur the market’s advancement. Particularly large demand has been established for the recombinant DNA-produced HGH technology. Recent developments include: In August 2023, FDA approved Opko Health, Inc. and Pfizer’s once-weekly somatrogon for children with growth hormone deficiency, key players are strategically advancing their presence in the market. The long-acting injectable, Somatrogon-ghla (Ngenla), demonstrates noninferiority to somatropin in improving annual height velocity based on phase 3 trial data. With a similar safety profile to somatropin, this approval reinforces Opko Health and Pfizer's commitment to addressing growth failure in children through innovative therapeutic solutions. , In May 2023, Novo Nordisk advanced in the human growth hormone therapy market with a favorable statement from the European Medicines Agency, recommending once-weekly Sogroya for children aged three and above, addressing growth hormone deficiency and development failure in adolescents. This positions Sogroya as a promising replacement therapy, signaling a noteworthy stride in Novo Nordisk's strategic foothold. .

Global human growth hormone market expansion is anticipated to achieve USD 15.66 billion by 2032 with a CAGR of 11.4% by 2032.

The size and share of this market is categorized based on Type (Recombinant Growth Hormones, Synthetic Growth Hormones) and Application (Growth Hormone Deficiency, Turner Syndrome, Prader-Willi Syndrome, Idiopathic Short Stature, HIV-related Wasting) and Route of Administration (Subcutaneous, Intramuscular, Intravenous) and geographical regions (North America, Europe, Asia-Pacific, South America, Middle-East and Africa).

The growth hormone deficiency market size was valued at USD 4.4 billion in 2024 and is projected to reach USD 9.3 billion by the end of 2037, rising at a CAGR of 7.3% during the forecast period, i.e., 2025 to 2037. North America industry is anticipated to capture a significant share of 41.8% by 2037 is attributable to the increased medical expenditure and advanced diagnostics technologies.

The Human Growth Hormone hGH market size is projected to grow from USD 3.88 Billion in the year 2021 to USD 8.67 Billion by 2029 at a CAGR of 6.69% from 2021-2029. Growth Hormone Deficiency was the largest segment with 36.25% share of total revenue generated in 2021. In Terms of Revenue, Intramuscular was the Leading segment with 38.97% Share of total Human Growth Hormone hGH Market in 2021. In Terms of Revenue, The Hospital Pharmacy was the Leading segment with 41.23% Share of total Human Growth Hormone hGH Market in 2021. North America was the dominated region with 32.15% of total revenue market share in 2021.

Surge in the prevalence of growth disorder in children:

Growth disorder refers to constitutional delay of growth and pubertal development. A child tends to be shorter than average and to enter puberty later than average, while growing at a normal rate. It is mainly affected because of disrupted hormones. It may be the result of injuries to the pituitary gland or brain. Cushing syndrome can impair height but cause weight gain. Precocious puberty is a condition caused by hormone problems. Owing to various factors, short stature is a common paediatric problem. According to WHO, 149 million children under 5 were estimated to be stunted in year 2020. Children with growth hormone deficiency have abnormality in the natural process of pituitary gland. This results in lack of hGH production in body. In such conditions, synthetic human growth hormone is injected to stave off some of the changes linked to aging, such as decreased muscle and bone mass. Hence, surge in the prevalence of growth disorder in children propel the growth of hGH market.Moreover, vigorous product pipeline and active R&D activities for the development of novel growth hormone therapies are expected to be the major factors driving the market for human growth hormones.For instance, Ascendis Pharma has TransCon hGH in clinical trial process for pediatric and adult growth hormone deficiency in Japan, China and other parts of world. Thus, surging R&D activities will create lucrative opportunities in the growth of hGH market.

Technological trends in Human Growth Hormone hGH:

Recent research trends of human growth hormone (hGH) are divided into improved first-generation products, long-acting second-generation products, and biosimilar products.The primary trend of hGH is to improve the first generation hGH by upgrading the injection device needed for administration for the convenience of patients. The second trend is developing a long-acting second generation hGH by extending the half-life of the first-generation hGH.The second-generation hGH development using Glycosylation, PEGylation, and Fc-fusion is actively being studied and is expected to be commercially available in the near future. The final trend is developing a biosimilar (similar biological product) product. The concept of the development of “biosimilar” is similar to that of the “generic products” of chemical drugs by supplying expensive biotherapeutics at a lower price for patients to give better treatment opportunities. hGH is a substance produced by pituitary gland, which spurs growth among children and adolescents. It also helps to regulate body composition, body fluids, muscle and bone growth. Besides, it allows proper regulation of sugar and fat metabolism and to some extent heart function as well. Synthetically produced hGH has been developed in 1985 and approved by FDA strictly for specific uses.Adults who have a growth hormone deficiency might be prescribed synthetic hGH by their health care provider. This may occur by a benign tumor on the pituitary gland (pituitary adenoma) or by treatment of an adenoma with surgery or radiotherapy. It is been approved by FDA in the treatment of adults with AIDS- or HIV-related growth hormone deficiency that causes irregular distribution of body fat.However, prolong use of hGH might cause a number of side effects for healthy adults, including: type 2 diabetes, joint and muscle pain, rise in insulin resistance, edema, and name a few.